Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Inclusion Criteria: * Recurrent, metastatic or progressive NSCLC without any indication of radiotherapy. Subjects must have: * Pathologically confirmed NSCLC * Previously received treatment with single agent Gefitinib or Erlotinib and completed treatment at least 2 weeks prior to study entry * Any one of the following: * A tumor that harbors an EGFR mutation * Objective clinical benefit from treatment with Gefitinib or Erlotinib as defined by either documented and confirmed partial or complete response (RECIST or WHO), or significant and durable (≥ 6 months) clinical benefit (stable disease as defined by RECIST or WHO) Progression of NSCLC while on continuous treatment with gefitinib or erlotinib as noted by CT/MRI increase in disease after having a confirmed partial or complete response or evidence of ≥ 6 months of SD within 3 months of study enrollment Exclusion Criteria: * Symptomatic brain metastasis * History of TIA, CVA, or thrombotic/thromboembolic event (within last 6 months) * History of hemoptysis greater than 10 mL/day within last 30 days * Uncontrolled or significant cardiovascular disease * History of uncontrolled diarrhea, Crohn's disease or ulcerative colitis * Inability to swallow tablets, untreated malabsorption or GI surgery that results in inability to absorb protocol therapy * Women unwilling to avoid pregnancy or use adequate contraception * History of allergy or adverse drug reaction to gefitinib or erlotinib